PT Kimia Farma Diagnostika

What PT Kimia Farma Diagnostika does

PT Kimia Farma Diagnostika (KFD) is a publicly listed Indonesian state-owned healthcare service provider, trading on the Indonesia Stock Exchange under ticker KFD. Founded in 2010 and headquartered in Jakarta, the company operates as the diagnostic and clinic arm of Biofarma Group (Holding BUMN Farmasi), the state-owned pharmaceutical holding company. Through its brand "Kimia Farma Laboratorium & Klinik," KFD runs a nationwide network of Klinik Utama (main clinics with emergency, specialist, hemodialysis, and comprehensive MCU services), Klinik Pratama (primary care with general medicine, dental, homecare, and BPJS kapitasi services), four divisions of laboratories (biomolecular, anatomic pathology, microbiology, and medical), vaccination centers (child, adult, international travel), genomic testing, and Mom & Baby services. Its technology stack consists of a corporate website with an outlet locator and geolocation, a branded mobile app (Kimia Farma Mobile, available on Google Play and the App Store), WhatsApp-based reservation, a 24/7 contact center (1500 255), and a Clinical Information System (CIS) and Back Office platform procured in October 2025.

The company's revenue model is multi-stream and transactional: clinical consultation and treatment fees, per-test laboratory diagnostics, vaccination services, MCU packages, hospital-grade services such as hemodialysis and emergency care, and billing through BPJS Kesehatan (Indonesia's national health insurance under Kapitasi Open Provider) and private insurance partners. Customer segments comprise individual patients (retail and BPJS-covered), corporate and enterprise clients (B2B wellness programs for entities such as OCBC, PT Vivere Group, and Pengadilan Negeri Kota Medan), insurance members, and community organizations reached through event-based outreach. Go-to-market is heavily event-driven, combining public health events, corporate wellness days, educational sponsorships, community outreach, and a digital presence across social media, with on-site service delivery for enterprise clients.

PT Kimia Farma Diagnostika serves as a vertically integrated node within the Biofarma Group ecosystem, co-branded with sister subsidiaries Kimia Farma Apotek (pharmacy retail) and PT Kimia Farma (pharmaceutical manufacturing), creating a closed-loop patient journey from screening and diagnosis through prescription to medication. Its core differentiators are state-owned enterprise status, nationwide physical reach, brand trust, and regulatory positioning within the Indonesian national health insurance framework.

Name

PT Kimia Farma Diagnostika

Legal name

PT Kimia Farma Diagnostika

Website

https://labkimiafarma.co.id

Company type

Public

Operating status

Operating

Headcount range

501–1,000 employees

Short description

PT Kimia Farma Diagnostika is a publicly listed Indonesian state-owned healthcare service provider operating a nationwide network of clinics, laboratories, vaccination centers, and genomic testing services, serving individual patients, corporate clients, and BPJS Kesehatan members as part of Biofarma Group.

Ownership category

akta.pro rank

Product category

Diagnostic Healthcare Services

NAICS

Medical and Diagnostic Laboratories (62151), Offices of Other Health Practitioners (6213), HMO Medical Centers (621491)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Medical Laboratories (8071), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Retail & Walk-In Primary Care Clinics (HLAFAGAC)

akta.pro secondary industries

Urinalysis & Routine Screening Diagnostics (HLAHAAAG), Lab Draws, Specimen Collection & Point-of-Care Testing (In-Home) (HSABACAN)

Keywords

• Clinical laboratory services
• Diagnostic healthcare services
• Vaccination services
• Medical check-up services
• Primary healthcare clinics

Headquarters

HQ city

Jakarta Pusat

HQ country

Indonesia

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales, Technology or R&D

Revenue model

1. Clinical Consultation and Treatment Services: Revenue generated from consultation fees at Klinik Utama and Klinik Pratama locations, covering general medicine, dental, and specialist services. Services include emergency care (Unit Gawat Darurat), hemodialysis, specialist consultations, and homecare.
2. Laboratory Diagnostic Services: Revenue from diagnostic testing across multiple lab types: Biomolecular, Anatomical Pathology, Microbiology, and Medical laboratories. Services are billed per test or as part of MCU packages.
3. Vaccination Services: Revenue from child vaccination, adult vaccination, and international travel vaccination services, offered at Klinik Pratama and dedicated vaccination outlet locations.
4. Medical Check-Up (MCU) Packages: Revenue from comprehensive medical check-up packages for individuals and corporate clients, including routine health screenings and tailored corporate wellness programs.
5. Insurance and BPJS Billing: Revenue from Kapitasi Open Provider arrangements with BPJS Kesehatan (Indonesian national health insurance) and various private insurance providers. Services covered under national health schemes.
6. Corporate Health Programs: Revenue from B2B corporate wellness contracts, including on-site health checks, routine employee health screenings (Prolanis), OCBC Health Day participation, and customized corporate MCU programs for organizations such as PT Vivere Group and Pengadilan Negeri Kota Medan.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

PT Kimia Farma Diagnostika operates a nationwide outpatient diagnostic and clinical services network under the Kimia Farma Laboratorium & Klinik brand. It delivers integrated healthcare through Klinik Utama (specialist clinics with emergency, hemodialysis, and comprehensive MCU), Klinik Pratama (primary care, dental, homecare), multi-disciplinary Laboratories (biomolecular, anatomic pathology, microbiology, medical), Vaccination services (child, adult, international travel), Medical Check-Up programs, Genomic Testing, and Mom & Baby services. Services are accessible to individual consumers (cash, BPJS, private insurance) and to corporate clients via on-site wellness programs and B2B contracts.

Product overview

PT Kimia Farma Diagnostika operates a multi-tiered healthcare service network as a unified platform. The core offering consists of Main Clinics (Klinik Utama) providing emergency services, hemodialysis, specialist consultations, and comprehensive medical check-ups; Primary Clinics (Klinik Pratama) offering general medicine, dental care, and homecare services; and specialized Laboratory Services encompassing biomolecular, anatomic pathology, microbiology, and medical testing divisions. Additional services include Vaccination (covering child, adult, and international travel vaccines), Mom & Baby care, Genomic Testing for genetic health assessment, and Medical Check-Up programs for both individual and corporate customers. The services are delivered through a nationwide network of outlets across Indonesia.

Differentiator

Problem solved

Functional benefit

Products and services

• Klinik Utama (Main Clinic) Main/specialist clinic service that provides emergency care, hemodialysis, specialist consultations, BPJS INACBG's coverage, and comprehensive medical check-ups under the Kimia Farma Laboratorium & Klinik brand. It is targeted at individual patients (including BPJS and private insurance holders) and corporate clients needing advanced outpatient care.
• Klinik Pratama (Primary Clinic) Primary care clinic offering general medicine (Poli Umum), dental care (Poli Gigi), Kapitasi Open Provider arrangements under BPJS Kesehatan, and homecare services. Targets individual patients (including BPJS participants) and family caregivers seeking convenient first-line outpatient care.
• Laboratory Services (Laboratorium) Comprehensive laboratory diagnostics service covering biomolecular testing, anatomic pathology, microbiology, and medical laboratory testing. Billed per test or as part of MCU packages. Serves individual patients, referring clinicians, and corporate clients.
• Vaksinasi (Vaccination Services) Comprehensive vaccination services delivered by dedicated vaccination teams in Klinik Pratama and dedicated vaccination outlets, covering child vaccination, adult vaccination, and international travel vaccination. Targets individuals, families, travelers, and corporate clients needing workforce immunization programs.
• Medical Check-Up (MCU) Comprehensive Medical Check-Up packages for individuals and corporate clients, including routine health screenings and tailored corporate wellness programs. Sold as packages and deployed on-site for enterprise clients (e.g., OCBC Health Day, PT Vivere Group, Pengadilan Negeri Kota Medan).
• Genomic Test Genetic and genomic testing services for health assessment and disease risk evaluation. Targets individuals seeking advanced preventive and personalized health insights, and clinicians requiring specialized diagnostic input.
• Mom & Baby Specialized healthcare services targeted at mothers and infants, complementing child vaccination and obstetric/pediatric support within the clinic network. Serves expecting mothers, new mothers, and parents of infants.
• Homecare Home-based healthcare services that bring medical care (nursing, sample collection, doctor visits) to patients at their residence. Targets patients with mobility limitations, post-treatment needs, and corporate clients needing at-home services.
• Unit Gawat Darurat (Emergency Unit) Emergency medical services within Klinik Utama offering immediate care for urgent health conditions. Targets walk-in patients needing acute outpatient emergency care.
• Hemodialisa (Hemodialysis) Kidney dialysis services for patients requiring renal therapy delivered within the Klinik Utama setting. Targets chronic kidney disease patients, including those managed under chronic disease (Prolanis) programs.

Quantifiable outcome

• Provided free health checks (rapid blood sugar, uric acid) to 200 participants at KAUJE FEST 2026
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Ten partnerships are on record, tiered moderate, minor and core.

• Forum Ekonomi Hijau (FEH) / IKA UNPADmoderateStrategic or Co-development Partner · 17 June 2026Kimia Farma Laboratorium & Klinik supported the Forum Ekonomi Hijau (Green Economy Forum) 2026 organized by IKA UNPAD (Padjadjaran University Alumni Association) on June 17, 2026, at PLN Kantor Pusat, Jakarta. The forum gathered policymakers, academics, business actors, government, and communities. Kimia Farma provided free health screenings (blood sugar, uric acid, cholesterol) for participants, reflecting commitment to promotive and preventive healthcare within sustainability initiatives.
• OCBC (Bank OCBC NISP)minorGTM or Marketing Partner · 1 June 2026Kimia Farma Laboratorium & Klinik participated in OCBC Health Day events held June 9-11, 2026 (OCBC Space) and June 17-19, 2026 (OCBC Tower). The company provided on-site health check services including injections, vaccinations, and health screenings for OCBC employees, with promotional giveaways for transactions, as part of OCBC's employee wellness programming.
• Takeda Pharmaceutical CompanymoderateStrategic or Co-development Partner · 1 May 2026Kimia Farma Laboratorium & Klinik collaborated with Takeda in an academic seminar on the importance of comprehensive dengue protection for all ages. The seminar aimed to educate healthcare professionals and the public on dengue prevention and management, leveraging Kimia Farma's diagnostic capabilities and Takeda's pharmaceutical expertise in dengue vaccines.
• SMP Labschool CibuburminorGTM or Marketing Partner · 1 January 2025Kimia Farma Laboratorium & Klinik served as a sponsor for the LASER (Labschool Art, Sport, Education, and Religion Competition) 2025 event organized by SMP Labschool Cibubur, held January 21-31, 2025. The sponsorship supported the educational and character-building competition with theme 'Sail to Victory, Compete for Glory', aligning with the company's community engagement and youth health awareness objectives.
• Biofarma Group (Holding BUMN Farmasi)coreStrategic or Co-development PartnerPT Kimia Farma Diagnostika is a member of Biofarma Group, Indonesia's state-owned pharmaceutical and healthcare holding company (BUMN Farmasi). The group comprises multiple healthcare subsidiaries including Kimia Farma (pharmaceutical manufacturing), Kimia Farma Apotek (pharmacy retail), KFTD (distribution), and KFLK (laboratory and clinic services). Membership provides brand authority, supply chain integration, regulatory credibility, and group-wide synergies.
• PT Vivere GroupminorGTM or Marketing PartnerKimia Farma Laboratorium & Klinik entered into a collaboration with PT Vivere Group (a furniture/lifestyle company) to improve employee health through on-site health check programs. The partnership involved health screening activities for Vivere Group employees, demonstrating the company's B2B corporate wellness service offerings.
• BPJS KesehatancoreStrategic or Co-development PartnerKimia Farma Laboratorium & Klinik is an accredited provider under Indonesia's national health insurance program (BPJS Kesehatan). The company operates as a 'Kapitasi Open Provider' under the BPJS system, providing covered healthcare services to insured patients and billing under national health insurance fee schedules.
• Pengadilan Negeri Kota MedanminorGTM or Marketing PartnerKimia Farma Diagnostika conducted a medical check-up program for employees of Pengadilan Negeri (District Court) Kota Medan, providing health screening services as part of the court's employee wellness program. This reflects the company's engagement with government sector clients for MCU services.
• Kimia Farma ApotekcoreStrategic or Co-development PartnerKimia Farma Apotek (pharmacy retail chain) is a sister subsidiary under Biofarma Group. Both entities are co-branded and cross-referenced on websites and in the field. The pharmacy chain provides prescription fulfillment and retail pharmacy services that complement Kimia Farma Diagnostika's diagnostic and clinical services, creating an integrated patient journey within the same group.
• PT Kimia Farma (Pharmaceutical Manufacturing)coreStrategic or Co-development PartnerPT Kimia Farma (the pharmaceutical manufacturing arm of Biofarma Group) is a sister subsidiary and co-branding partner. The company's laboratory and clinic services interface with pharmaceutical products manufactured by PT Kimia Farma, creating vertical integration within the group ecosystem.

Scale indicators1 record

Recent moves6 records

Expansion highlights10 records

Direct peers

• Prodia Widya Husada: Indonesia's largest independent clinical laboratory chain, publicly listed (ticker PRDA). Competes directly with Kimia Farma Diagnostika's medical laboratory, MCU, and preventive health screening offerings across similar customer segments (individuals, corporates, doctors).
• Pertamedika Indonesia Healthcare Corporation (IHC): State-owned hospital and clinic network under Pertamina; directly comparable as another Indonesian state-owned healthcare provider operating clinics, labs, and corporate health services that overlap with Kimia Farma Diagnostika's BUMN-backed model.

Broad incumbents

• Mitra Keluarga Karyasehat (Mitra Keluarga Hospitals): Indonesian hospital operator (ticker MIKA) with a broad network of general hospitals. A larger-scale incumbent whose primary care, diagnostics, and MCU offerings overlap with KFD's clinic and lab services.
• Siloam International Hospitals: Largest private hospital network in Indonesia (ticker SILO), part of Lippo Group. Broader incumbent offering inpatient and outpatient services across many specialties, overlapping with KFD's Klinik Utama (emergency, specialist, hemodialysis) and lab services.
• PT Bundamedik (BMHS): Indonesian listed healthcare group (ticker BMHS) operating hospitals, mother & child clinics, and diagnostic services. Comparable to KFD in offering multi-site clinical, diagnostic, and women/child health services across Indonesia.
• Hermina Hospitals (HMIJ): Indonesian publicly listed hospital group (ticker HMIJ) focused on mother & child and general hospital services. Overlaps with KFD's Klinik Utama services, Mom & Baby offering, and primary care footprint.

Emerging players

• Bumame Farmasi: Rapidly growing Indonesian diagnostic chain offering lab testing, MCU, vaccinations, and homecare with a digital-first UX. Direct competitor to KFD's lab and homecare services, particularly targeting younger urban consumers.

Others

• Kimia Farma Apotek: Sister subsidiary under Biofarma Group operating Kimia Farma's pharmacy retail chain. Complements KFD's clinical/diagnostic services via prescription fulfillment and cross-referrals — a closely aligned ecosystem participant rather than direct competitor.
• Biofarma (PT Bio Farma): Parent holding/state-owned vaccine manufacturer that owns Kimia Farma Diagnostika and other healthcare subsidiaries. Adjacent ecosystem participant — supplies vaccines, provides group-level synergies, and shares regulatory standing relevant to KFD.

Regional players

• Parahita Diagnostic Center: Indonesian diagnostic laboratory network headquartered in Surabaya, with strong East Java presence. Comparable lab/MCU offering to KFD, primarily competing in regional rather than fully national footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/kaeflabklinik
• YouTubeyoutube.com/@kaeflabklinik
• Facebookfacebook.com/61552565858602
• Instagraminstagram.com/kimiafarmalab_klinik
• TikToktiktok.com/@kimiafarmalab_klinik?is_from_webapp=1&sender_device=pc
• LinkedInlinkedin.com/company/pt-kimia-farma-diagnostika

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PT Kimia Farma Diagnostika